'Walking Ebola' strain's slow progression complicates Congo outbreak response

In the Democratic Republic of Congo, a peculiar form of Ebola is spreading in a way that defies the usual urgency of the disease. The Bundibugyo strain replicates slowly enough that infected people can remain on their feet, moving through their communities, shedding virus, while still feeling sick enough to function. Doctors have begun calling it "walking Ebola"—a clinical observation that carries both a glimmer of hope and a deepening crisis.

Corri Levine, a virologist at the University of Texas Medical Branch, spent years studying Bundibugyo in a biocontainment laboratory before it became the fastest-growing Ebola outbreak on record. Her doctoral research had shown that this strain multiplies more slowly than the Zaire variant that devastated West Africa a decade ago. When the Congo outbreak began, the pattern she observed in patients aligned with what she had found in her lab work. "It's this longer, prolonged disease course," she explained, describing how the virus allows people to feel unwell enough to transmit infection but not so devastated that they are bedridden. The realization struck her as an "aha moment"—a biological fact that might reshape how doctors approach treatment.

That slower progression, paradoxically, creates an opening. Ebola patients have always had their best chance of survival when they reach treatment early, before viral replication spirals into septic shock and organ failure. If Bundibugyo's leisurely pace through the body gives clinicians a longer window to intervene, antiviral drugs might actually work. Levine's laboratory experiments showed that remdesivir, an antiviral made by Gilead Sciences, was more effective against Bundibugyo than against Zaire Ebola in cell cultures. In July, researchers began testing remdesivir alongside an antibody therapy called MBP134 in a World Health Organisation-sponsored clinical trial in Congo. A separate study is evaluating an experimental oral antiviral, obeldesivir, in people recently exposed to the virus.

But the outbreak is accelerating faster than treatment can keep pace. Deaths nearly doubled in July. More than ninety percent of confirmed deaths are occurring before patients ever reach a treatment centre. Four out of every five new infections now arise outside known transmission chains, suggesting the virus is spreading through the community in ways health authorities cannot track. Congo has recorded 2,181 confirmed cases and 864 deaths—a case-fatality ratio of forty percent. Overcrowded Ebola units and diagnostic delays mean infected people remain in their communities longer, fueling further transmission.

Convincing people to seek care has always been Ebola's cruelest obstacle. During the West African epidemic, which infected more than 28,000 people, many saw treatment centres as places to die rather than places to recover, because no vaccines or proven treatments existed. Joanne Liu, who led Doctors Without Borders' response to that outbreak, remembers the fear. Today, the evidence is clearer: patients who reach care have three to four times better odds of survival than those who remain in their communities, according to Chikwe Ihekweazu, the WHO's executive director for health emergencies.

The West African epidemic transformed Ebola treatment from isolation wards into intensive-care facilities. Daniel Chertow, a critical-care physician at the US National Institutes of Health who treated Ebola patients in Liberia, describes the shift: treating Ebola means supporting the whole person—aggressive fluid resuscitation, shock management, respiratory support, organ-failure management, alongside antivirals and antibodies. If Levine's hypothesis holds, Bundibugyo's slower progression may give clinicians the time they need to deliver that full spectrum of care before the disease becomes irreversible.

Yet the outbreak is also a warning. This Bundibugyo outbreak has already generated more than ten times as many confirmed cases as the two previous Bundibugyo outbreaks combined. The more the virus circulates, the more opportunity it has to mutate. Pardis Sabeti, a geneticist at the Broad Institute of MIT and Harvard, whose Sentinel programme is supporting genomic sequencing in Congo, notes that any genetic change could alter the virus's biology in unpredictable ways. When Levine began her doctoral work nearly a decade ago, Bundibugyo had caused only two small outbreaks and attracted little scientific attention. "Everybody's like, 'Oh, it's just that little one,'" she recalled. Today it is the third-largest Ebola outbreak on record, and the obscure virus that once seemed minor has become one of the most urgent questions in global health.